Alfredo A Sadun

Dr. Alfredo A Sadun


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2015 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LGLuca Giordano
Luca Giordano
SDS Deceglie
S Deceglie
ADAdamo Pio d'Adamo
Adamo Pio d'Adamo
MVM L Valentino
M L Valentino
Chiara La MorgiaChiara La Morgia
Chiara La Morgia
PCPALMIRO CANTATORE
PALMIRO CANTATORE
Leber’s hereditary optic neuropathy (LHON), the most frequent mitochondrial disease, is associated with mitochondrial DNA (mtDNA) point mutations affecting Complex I subunits, usually homoplasmic. This blinding disorder is characterized by incomplete penetrance, possibly related to several genetic modifying factors. We recently reported that increased mitochondrial biogenesis in unaffected mutation carriers is a compensatory mechanism, which reduces penetrance. Also, environmental factors such as cigarette smoking have been implicated as disease triggers. To investigate this issue further, we first assessed the relationship between cigarette smoke and mtDNA copy number in blood cells from large cohorts of LHON families, finding that smoking was significantly associated with the lowest mtDNA content in affected individuals. To unwrap the mechanism of tobacco toxicity in LHON, we exposed fibroblasts from affected individuals, unaffected mutation carriers and controls to cigarette smoke condensate (CSC). CSC decreased mtDNA copy number in all cells; moreover, it caused significant reduction of ATP level only in mutated cells including carriers. This implies that the bioenergetic compensation in carriers is hampered by exposure to smoke derivatives. We also observed that in untreated cells the level of carbonylated proteins was highest in affected individuals, whereas the level of several detoxifying enzymes was highest in carriers. Thus, carriers are particularly successful in reactive oxygen species (ROS) scavenging capacity. After CSC exposure, the amount of detoxifying enzymes increased in all cells, but carbonylated proteins increased only in LHON mutant cells, mostly from affected individuals. All considered, it appears that exposure to smoke derivatives has a more deleterious effect in affected individuals, whereas carriers are the most efficient in mitigating ROS rather than recovering bioenergetics. Therefore, the identification of genetic modifiers that modulate LHON penetrance must take into account also the exposure to environmental triggers such as tobacco smoke.

28 August 2020 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Open access
VBValérie Biousse
Valérie Biousse
NNNancy J. Newman
Nancy J. Newman
PYPatrick Yu-Wai-Man
Patrick Yu-Wai-Man
Valerio CarelliValerio Carelli
Valerio Carelli
MMMark L. Moster
Mark L. Moster
FGfor the LHON Study Group
for the LHON Study Group
Background: RESCUE and REVERSE were 2 Phase 3 clinical trials that assessed the efficacy and safety of intravitreal gene therapy with lenadogene nolparvovec (rAAV2/2-ND4) for the treatment of Leber hereditary optic neuropathy (LHON). RESTORE is the long-term follow-up study of subjects treated in the RESCUE and REVERSE trials. Methods: In RESCUE and REVERSE, 76 subjects with LHON because of the m.11778 G>A mutation in the mitochondrial gene ND4 received a single unilateral intravitreal injection of lenadogene nolparvovec. After 96 weeks, 61 subjects were enrolled in the long-term follow-up study RESTORE. The best-corrected visual acuity (BCVA) was assessed over a period of up to 52 months after onset of vision loss. A locally estimated scatterplot smoothing regression model was used to analyze changes in BCVA over time. Vision-related quality of life was reported using the visual function questionnaire-25 (VFQ-25). Results: The population of MT-ND4 subjects enrolled in RESTORE was representative of the combined cohorts of RESCUE and REVERSE for mean age (35.1 years) and gender distribution (79% males). There was a progressive and sustained improvement of BCVA up to 52 months after the onset of vision loss. The final mean BCVA was 1.26 logarithm of the minimal angle of resolution 48 months after the onset of vision loss. The mean VFQ-25 composite score increased by 7 points compared with baseline. Conclusion: The treatment effect of lenadogene nolparvovec on BCVA and vision-related quality of life observed 96 weeks (2 years) after treatment in RESCUE and REVERSE was sustained at 3 years in RESTORE, with a maximum follow-up of 52 months (4.3 years) after the onset of vision loss.

10 December 2015 in Brain
Verified
Journal Article
Open access
PDF file
Valerio CarelliValerio Carelli
Valerio Carelli
PDPio D’adamo
Pio D’adamo
MVMaria Lucia Valentino
Maria Lucia Valentino
CMChiara La Morgia
Chiara La Morgia
FRFred N. Ross-Cisneros
Fred N. Ross-Cisneros
ASAlfredo A Sadun
Alfredo A Sadun
This is the older brother of Case 1 who also was an agricultural worker exposed to pesticides. Like his brother, Case 2 smoked heavily (homemade cigarettes abou

28 September 2021 in International Ophthalmology Clinics
Verified
Journal Article
Open access
JSJosé-Alain Sahel
José-Alain Sahel
NNNancy J. Newman
Nancy J. Newman
PYPatrick Yu-Wai-Man
Patrick Yu-Wai-Man
CVCatherine Vignal-Clermont
Catherine Vignal-Clermont
Valerio CarelliValerio Carelli
Valerio Carelli
MTMagali Taiel
Magali Taiel

18 December 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
PBPiero Barboni
Piero Barboni
Chiara La MorgiaChiara La Morgia
Chiara La Morgia
MCMaria Lucia Cascavilla
Maria Lucia Cascavilla
EHEun Hee Hong
Eun Hee Hong
MBMarco Battista
Marco Battista
PYPatrick Yu-Wai-Man
Patrick Yu-Wai-Man

21 September 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JFJack T. Fuller
Jack T. Fuller
SBSteven Barnes
Steven Barnes
LSLorenzo A. Sadun
Lorenzo A. Sadun
PAPujan Ajmera
Pujan Ajmera
AAAnastassia N. Alexandrova
Anastassia N. Alexandrova
ASAlfredo A Sadun
Alfredo A Sadun
How does a single amino acid mutation occurring in the blinding disease, Leber’s hereditary optic neuropathy (LHON), impair electron shuttling in mitochondria? We investigated changes induced by the m.3460 G>A mutation in mitochondrial protein ND1 using the tools of Molecular Dynamics and Free Energy Perturbation simulations, with the goal of determining the mechanism by which this mutation affects mitochondrial function. A recent analysis suggested that the mutation’s replacement of alanine A52 with a threonine perturbs the stability of a region where binding of the electron shuttling protein, Coenzyme Q10, occurs. We found two functionally opposing changes involving the role of Coenzyme Q10. The first showed that quantum electron transfer from the terminal Fe/S complex, N2, to the Coenzyme Q10 headgroup, docked in its binding pocket, is enhanced. However, this positive adjustment is overshadowed by our finding that the mobility of Coenzyme Q10 in its oxidized and reduced states, entering and exiting its binding pocket, is disrupted by the mutation in a manner that leads to conditions promoting the generation of reactive oxygen species. An increase in reactive oxygen species caused by the LHON mutation has been proposed to be responsible for this optic neuropathy.